The United Laboratories International Unit Gets Clinical Trial Nod for Chronic Kidney Disease Drug

Like
Comment
Favorite

The United Laboratories International Unit Gets Clinical Trial Nod for Chronic Kidney Disease Drug

MT Newswires Live01-23

China's medical products administrator approved The United Laboratories International (HKG:3933) unit United Bio-Technology (Hengqin)'s phase 2 trial for its UBT251 injection for chronic kidney disease.

The drug exhibits effectiveness against glucagon-like peptide-1 which causes obesity, diabetes, and other factors, that ultimately also damage the kidneys, the filing said.

Shares rose 2% during Thursday's morning trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

21:28
Vroom Inc to Offer 3,957,621 Shares of Common Stock - SEC Filing
21:28
Vroom Inc -Files Prospectus Relates to Potential Offer & Sale From Time to Time by Mudrick Capital Management
21:26
Global Partners Lp - on March 20, Enters Eleventh Amendment to Credit and Security Agreements - SEC Filing
21:25
Mattel Inc Says CEO Ynon Kreiz's 2024 Total Compensation Was $37.8 Mln- SEC Filing
21:22
Kuke Music Successfully Reached Strategic Partnership With China Media Group Iov Digital Media, Aims to Redefining the Benchmark for in-Vehicle Music

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2505121039?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-23 11:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505121039","market":"us","top_or_hot":-1,"title":"The United Laboratories International Unit Gets Clinical Trial Nod for Chronic Kidney Disease Drug","media":"MT Newswires Live","content":"<html><body><p> China's medical products administrator approved The United Laboratories International (HKG:3933) unit United Bio-Technology (Hengqin)'s phase 2 trial for its UBT251 injection for chronic kidney disease.</p><p>The drug exhibits effectiveness against glucagon-like peptide-1 which causes obesity, diabetes, and other factors, that ultimately also damage the kidneys, the filing said.</p><p>Shares rose 2% during Thursday's morning trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The United Laboratories International Unit Gets Clinical Trial Nod for Chronic Kidney Disease Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe United Laboratories International Unit Gets Clinical Trial Nod for Chronic Kidney Disease Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-23 11:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's medical products administrator approved The United Laboratories International (HKG:3933) unit United Bio-Technology (Hengqin)'s phase 2 trial for its UBT251 injection for chronic kidney disease.</p><p>The drug exhibits effectiveness against glucagon-like peptide-1 which causes obesity, diabetes, and other factors, that ultimately also damage the kidneys, the filing said.</p><p>Shares rose 2% during Thursday's morning trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505121039","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505121039","pubTimestamp":1737602696,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's medical products administrator approved The United Laboratories International  unit United Bio-Technology 's phase 2 trial for its UBT251 injection for chronic kidney disease.The drug exhibits effectiveness against glucagon-like peptide-1 which causes obesity, diabetes, and other factors, that ultimately also damage the kidneys, the filing said.Shares rose 2% during Thursday's morning trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK4211":"区域性银行","BK1191":"制药","UBCP":"联合合众银行"},"translate_title":"联邦制药国际部门获得慢性肾病药物临床试验认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":0.9,"UBCP":1},"content_text":"China's medical products administrator approved The United Laboratories International (HKG:3933) unit United Bio-Technology (Hengqin)'s phase 2 trial for its UBT251 injection for chronic kidney disease.The drug exhibits effectiveness against glucagon-like peptide-1 which causes obesity, diabetes, and other factors, that ultimately also damage the kidneys, the filing said.Shares rose 2% during Thursday's morning trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}